

IN THE CLAIMS

1. (CURRENTLY AMENDED) A method for treating a patient having a seborrheic keratosis condition affecting at least one layer of skin comprising administering in situ by topical application or injection a physiologically acceptable formulation consisting essentially of trypsin in an amount of the formulation having a trypsin concentration selected from the ranges of from about 1×10^{-5} % w/v to about 1×10^{-3} % w/v or from about 1 % w/v to about 10 % w/v applied directly or indirectly and for a duration effective to selectively regulate removal of said condition.

2. (ORIGINAL) The method of claim 1 wherein said layer of skin is selected from the group consisting of an epidermal layer, a dermal layer, a subcutaneous layer, and combinations thereof.

3-23. CANCELED

24. (CURRENTLY AMENDED) A method to treat at least one affected layer of skin comprising topically applying to an outermost layer of said affected skin a composition consisting essentially of trypsin in a biologically acceptable formulation applied directly or indirectly and in an amount to selectively regulate removal of at least one epidermal layer containing a skin condition to thereby treat said skin wherein the formulation has a trypsin concentration selected from the ranges of from about 1×10^{-5} % w/v to about 1×10^{-3} % w/v or from about 1 % w/v to about 10 % w/v and wherein said skin condition is seborrheic keratosis.

25-30. CANCELED

31. (PREVIOUSLY PRESENTED) The method of claim 24 wherein said at least one affected layer of skin is selected from the group consisting of an epidermal layer, a dermal layer, a subcutaneous layer, and combinations thereof.

32-37. CANCELED

38. (PREVIOUSLY PRESENTED) The method of claim 1 wherein the composition is applied one time.

39-63. CANCELED

64. (CURRENTLY AMENDED) A method for treating a patient having a seborrheic keratosis condition affecting at least one layer of skin, the method comprising administering in situ by topical application applied directly or indirectly or by injection a physiologically acceptable formulation consisting essentially of trypsin in an amount of the formulation having a trypsin concentration selected from the ranges of from about 1×10^{-5} % w/v to about 1×10^{-3} % w/v or from about 1 % w/v to about 10 % w/v

w/v and for a duration effective to selectively regulate removal of said condition wherein the formulation is administered in a single application for about 15 minutes, three applications for about five minutes each, six applications for about three minutes each, one application a day, two applications a day, one application every other day, or 1-10 applications a day.

65. (PREVIOUSLY PRESENTED) The method of claim 64 wherein said layer of skin is selected from the group consisting of an epidermal layer, a dermal layer, a subcutaneous layer, and combinations thereof.